MedTrace Logo

A First-in-human Study of YN001 in Healthy Volunteers

NCT05635084 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-11-18

No results posted yet for this study

Summary

This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.

Conditions

Interventions

DRUG

YN001

Dose ranges from 2-90mg

DRUG

Placebo for YN001

5% dextrose injection to mimic the YN001

Sponsors & Collaborators

  • Beijing Inno Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ofer Gonen, Ph.D · Nucleus Network Pty Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-16
Primary Completion
2024-08-09
Completion
2024-08-09

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05635084 on ClinicalTrials.gov